Kiniksa Pharmaceuticals InteKNSA
ASignal's systematic analysis rates KNSA as Bullish.
Reflects the latest available analysis · analyzed Sep 1, 2026
The case on KNSA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (55.4% YoY)
- High gross margin (54.50%) indicating pricing power
- Exceptional financial health with debt-to-equity of 0.01x
- High cash balance ($525.93M) and strong current ratio (3.90x)
- Positive free cash flow ($126.14M)
- Return on equity of 14.04%, above threshold for capital efficiency
- Overvalued on P/E (78.63x) and forward P/E (48.61x)
- High EV/EBITDA of 55.06x suggesting premium valuation
- Negative price momentum (-0.0069)
- MACD below signal line with negative histogram
- No Reddit mentions indicating low retail interest
See the full verdict on KNSA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes KNSA
Most investors never get a second opinion, let alone several. ASignal runs KNSA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.